Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2436058

CC1(C)Cc2cc(F)cc(C[P+](c3ccccc3)(c3ccccc3)c3ccccc3)c2O1.[Cl-]

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
FFAR4 Q5NUL3 7/20 0.33
GYS1 P13807 1/20 0.33
KMT2A Q03164 1/20 0.32
DHFR P00374 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL8630306 0.80 LMNA (0.39) KDM5AKDM4CALDH1A1MAPTKMT2A
SCHEMBL12035780 0.76 ALDH1A1 (0.34) KDM5AKDM4CALDH1A1MAPTFFAR4
SCHEMBL16142481 0.76 ALDH1A1 (0.34) KDM5AKDM4CALDH1A1MAPTFFAR4
SCHEMBL12035969 0.74 FFAR4 (0.39) KDM5AKDM4CALDH1A1MAPTFFAR4
SCHEMBL2431904 0.74 HTR2A (0.40) KDM5AKDM4CALDH1A1MAPTFFAR4
Bromide SCHEMBL5784209 0.73 NPC1 (0.39) KMT2A
SCHEMBL2436876 0.69 ESR1 (0.38) ALDH1A1MAPTFFAR4GYS1KMT2A
SCHEMBL14564975 0.69 DHFR (0.43) ALDH1A1MAPTFFAR4GYS1DHFR
SCHEMBL9983222 0.69 MAOB (0.40) KDM5AKDM4CFFAR4GYS1KMT2A
SCHEMBL14796812 0.68 KMT2A (0.37) KDM5AKDM4CFFAR4GYS1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2014-05-01 US disclosed
US-8598374-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-12-03 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-23 US disclosed
US-20130109734-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-02 US disclosed
EP-2582674-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2013-04-24 EP disclosed
EP-2367793-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX INC (US) 2013-03-27 EP disclosed
US-8309600-B2 GPR120 receptor agonists and uses thereof METABOLEX INC. (US) 2012-11-13 US disclosed
US-8299117-B2 GPR120 receptor agonists and uses thereof METABOLEX INC. (US) 2012-10-30 US disclosed
EP-2514745-A1 GPR120 receptor agonists and uses thereof Metabolex Inc. (US) 2012-10-24 EP disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 US disclosed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 WO disclosed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 EP disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM5A 4576/4885KDM4C 4698/4885ALDH1A1 3347/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM5A 4576/4885KDM4C 4698/4885ALDH1A1 3347/4885
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM5A 4576/4885KDM4C 4698/4885ALDH1A1 3347/4885
US-20130109734-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM5A 4576/4885KDM4C 4698/4885ALDH1A1 3347/4885
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM5A 4576/4885KDM4C 4698/4885ALDH1A1 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.